HDM_SARS2_Spike_del21_D614G Citations (14)

Originally described in: Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.
Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD Viruses. 2020 May 6;12(5). pii: v12050513. doi: 10.3390/v12050513. PubMed Journal

---

Articles Citing HDM_SARS2_Spike_del21_D614G

Articles
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Greaney AJ, Starr TN, Gilchuk P, Zost SJ, Binshtein E, Loes AN, Hilton SK, Huddleston J, Eguia R, Crawford KHD, Dingens AS, Nargi RS, Sutton RE, Suryadevara N, Rothlauf PW, Liu Z, Whelan SPJ, Carnahan RH, Crowe JE Jr, Bloom JD. Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9. doi: 10.1016/j.chom.2020.11.007. Epub 2020 Nov 19. PubMed
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6. doi: 10.1016/j.chom.2021.02.003. Epub 2021 Feb 8. PubMed
The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD. Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. bioRxiv. 2021 Apr 14. doi: 10.1101/2021.04.14.439844. PubMed
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Greaney AJ, Loes AN, Gentles LE, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. Sci Transl Med. 2021 Jun 30;13(600). pii: scitranslmed.abi9915. doi: 10.1126/scitranslmed.abi9915. Epub 2021 Jun 8. PubMed
Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. Ellis D, Brunette N, Crawford KHD, Walls AC, Pham MN, Chen C, Herpoldt KL, Fiala B, Murphy M, Pettie D, Kraft JC, Malone KD, Navarro MJ, Ogohara C, Kepl E, Ravichandran R, Sydeman C, Ahlrichs M, Johnson M, Blackstone A, Carter L, Starr TN, Greaney AJ, Lee KK, Veesler D, Bloom JD, King NP. Front Immunol. 2021 Jun 29;12:710263. doi: 10.3389/fimmu.2021.710263. eCollection 2021. PubMed
Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2. Sun X, Yang S, Al-Dossary AA, Broitman S, Ni Y, Guan M, Yang M, Li J. Appl Environ Microbiol. 2022 Mar 8;88(5):e0230321. doi: 10.1128/aem.02303-21. Epub 2022 Jan 5. PubMed
T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components. Jing L, Wu X, Krist MP, Hsiang TY, Campbell VL, McClurkan CL, Favors SM, Hemingway LA, Godornes C, Tong DQ, Selke S, LeClair AC, Pyo CW, Geraghty DE, Laing KJ, Wald A, Gale M Jr, Koelle DM. JCI Insight. 2022 Mar 22;7(6). pii: 158126. doi: 10.1172/jci.insight.158126. PubMed
A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. Greaney AJ, Starr TN, Eguia RT, Loes AN, Khan K, Karim F, Cele S, Bowen JE, Logue JK, Corti D, Veesler D, Chu HY, Sigal A, Bloom JD. PLoS Pathog. 2022 Feb 8;18(2):e1010248. doi: 10.1371/journal.ppat.1010248. eCollection 2022 Feb. PubMed
Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1. Windsor IW, Tong P, Lavidor O, Moghaddam AS, McKay LGA, Gautam A, Chen Y, MacDonald EA, Yoo DK, Griffths A, Wesemann DR, Harrison SC. Sci Immunol. 2022 Aug 12;7(74):eabo3425. doi: 10.1126/sciimmunol.abo3425. Epub 2022 Aug 12. PubMed
Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Chen Y, Tong P, Whiteman N, Moghaddam AS, Zarghami M, Zuiani A, Habibi S, Gautam A, Keerti F, Bi C, Xiao T, Cai Y, Chen B, Neuberg D, Wesemann DR. Sci Immunol. 2022 May 12:eabp8328. doi: 10.1126/sciimmunol.abp8328. PubMed
The Integral Membrane Protein ZMPSTE24 Protects Cells from SARS-CoV-2 Spike-Mediated Pseudovirus Infection and Syncytia Formation. Shilagardi K, Spear ED, Abraham R, Griffin DE, Michaelis S. mBio. 2022 Oct 26;13(5):e0254322. doi: 10.1128/mbio.02543-22. Epub 2022 Oct 5. PubMed
Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARS-CoV-2. Kim J, Jozic A, Mukherjee A, Nelson D, Chiem K, Khan MSR, Torrelles JB, Martinez-Sobrido L, Sahay G. Adv Sci (Weinh). 2022 Dec;9(35):e2202556. doi: 10.1002/advs.202202556. Epub 2022 Oct 10. PubMed
The anti-SARS-CoV-2 effect and mechanism of Chiehyuan herbal oral protection solution. Wu CY, Yang YH, Lin YS, Shu LH, Cheng YC, Liu HT, Lin YY, Lee IY, Shih WT, Yang PR, Tsai YY, Chang GH, Hsu CM, Yeh RA, Wu YH, Wu YH, Shen RC, Tsai MS. Heliyon. 2023 Jul 3;9(7):e17701. doi: 10.1016/j.heliyon.2023.e17701. eCollection 2023 Jul. PubMed
Targeting spike glycans to inhibit SARS-CoV2 viral entry. Guseman AJ, Rennick LJ, Nambulli S, Roy CN, Martinez DR, Yang DT, Bhinderwala F, Vergara S, Schaefer A, Baric RS, Ambrose Z, Duprex WP, Gronenborn AM. Proc Natl Acad Sci U S A. 2023 Sep 19;120(38):e2301518120. doi: 10.1073/pnas.2301518120. Epub 2023 Sep 11. PubMed

If you have published an article using this material, please email us at to have your article added to this page.